

### 3 SAFETY

Each test was carried out with CLOTHOLINE® BG at a maximal concentration of 10% in the solvent.

	Year	Guideline	Method	Model	Results
Ocular irritation	2014		Neutral Red	Rabbit cornea fibroblasts (SIRC line)	Relative low cytotoxicity
Phototoxicity	2014	OCDE 432	Neutral Red	Mouse fibroblasts 3T3	Non phototoxic
Cutaneous irritation	2014	OCDE 439	Blue formazan crystal Spectrophotometry	SkinEthic Reconstituted human epidermis	Non irritant
Mutagenicity	2014	OCDE 471	Ames test	Salmonellas	Non mutagenic Non pro-mutagenic
Patch Test	2014		Semi-occlusive patch 48h contact with the skin	10 Volunteers	Non irritant
Sensitisation	2014		Marzulli-Maibach sensitisation method (9-RIPT)	52 Volunteers	No significant reaction Can be considered "hypoallergenic"

A safety assessment on Clotholine®MPD concluded on the use which should not pose toxicity problems for a maximum of 1%/day in adults for leave-on products for face (Method according EU-SCCS's recommendations, 2014).

A safety assessment on Clotholine®LV concluded on the use which should not pose toxicity problems for a maximum of 1%/day in adults for leave-on products for face (Method according EU-SCCS's recommendations, 2014).

### 4 FORMULATION

<b>Formulation</b>	Water-in-oil / oil-in-water emulsion Add in final stage of formulation Dosage recommendation 1% Water dispersible For cosmetic use only
<b>Conditions of use</b>	T < 40°C pH range 5-7
<b>Particularities</b>	No known incompatibility Could decrease the viscosity of a silicon base

### 5 BIBLIOGRAPHY

ALDRICH, JOHN. **Correlations Genuine and Spurious in Pearson and Yule**. *Statistical Science*. 1995.

ALEXANDER R. T., WOUDEBERG-VRENKEN T. E., BUURMAN J., DIJKMAN H., VAN DER EERDEN B., VAN LEEUWEN J., BINDELS R. AND HOENDEROP J. **Klotho Prevents Renal Calcium Loss**, *American Society of Nephrology*. 2009.